Moreover, a flecainide analogue that lacks RyR2-blocking properties was unable to prevent CPVT [137], clearly indicating that the primary mode of action of flecainide in CPVT is inhibition of RyR2. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.